生物标志物用于卵巢癌女性手术分层:科学影响论文第69号 2022年5月
本文聚焦利用体液或组织中的生物分子对卵巢癌患者进行诊断和结局预测,指出化疗领域已有生物标志物指导治疗,但指导手术分层的研究极少;需开展研究识别新标志物并评估其临床有效性,以推动基于肿瘤生物学特征的个体化手术。
要点
- 生物标志物可用于卵巢癌诊断及结局预测,并基于肿瘤特征制定个体化治疗计划。
- 化疗已有生物标志物指导治疗,但指导卵巢癌手术分层的研究极少。
- 需研究识别新标志物并评估其临床有效性,以指导个体化手术。
核心结论
- 生物标志物可能为临床诊断及疾病可能的病程和结局提供意想不到的见解。
- 需开展研究识别新生物标志物并评估其在临床环境中的有效性,以帮助识别特定肿瘤类型指导手术。
- 生物标志物可帮助判断手术切除病变是否成功,或帮助识别化疗后持续存在的肿瘤沉积。
研究设计与样本
- 本文为科学影响论文(Scientific Impact Paper No. 69),由皇家学院(Royal College)于2022年5月发布。
主要发现
- 在癌症诊疗中,生物标志物正被用于根据肿瘤独特特征为患者制定个体化治疗计划。
- 手术是卵巢癌核心治疗之一,可作为初次手术或在化疗后延迟手术中提供。
- 化疗领域已有生物标志物指导肿瘤治疗,但确定生物标志物在卵巢癌手术分层中价值的研究极少。
临床怎么用
- 作者指出,上述方面均将改善当前实践。
- 作者指出,本科学影响论文强调的研究可能为根据肿瘤生物学特征定制手术铺平道路,并帮助妇科肿瘤医生根据个体需求提供手术治疗,而非对所有患者采用一刀切方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarkers may offer unforeseen insights into clinical diagnosis, as well as the likely course and outcome of a condition. In this paper, the focus is on the use of biological molecules found in body fluids or tissues for diagnosis and prediction of outcome in ovarian cancer patients. In cancer care, biomarkers are being used to develop personalised treatment plans for patients based on the unique characteristics of their tumour. This tailoring of care can be used to pursue specific targets identified by biomarkers, or treat the patient according to specific tumour characteristics. Surgery is one of the core treatments for ovarian cancer, whether it is offered in primary surgery or following chemotherapy in delayed surgery. Biomarkers already exist to guide the treatment of tumours with chemotherapy, but very little research has determined the value of biomarkers in tailoring surgical care for ovarian cancer. Such research is required to identify new biomarkers and assess their effectiveness in a clinical setting as well as to help identify specific tumour types to guide surgery. Biomarkers could help to determine the success of removing the disease surgically, or help to identify tumour deposits that persist after chemotherapy. All of these aspects would improve current practice. This Scientific Impact Paper highlights research that may pave the way towards bespoke surgery according to the biological characteristics of a tumour and aid gynaecological oncologists to provide surgical treatment according to individual need, rather than a blanket approach for all.
引用
- Phelps DL, Borley JV, Brown R, et al. The use of biomarkers to stratify surgical care in women with ovarian cancer: Scientific Impact Paper No. 69 May 2022. BJOG. 2022. PMID: 35437905. doi:10.1111/1471-0528.17142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。